Remixpoint
3825
Sanrio
8136
Nippon Telegraph & Telephone
9432
4
Metaplanet
3350
5
Rakuten Group
4755
JP Stock MarketDetailed Quotes
4575 CanBas
- 1044
- +37+3.67%
20min DelayMarket Closed Feb 17 15:30 JST
19.95BMarket Cap-15.38P/E (Static)
1062High981Low435.40KVolume989Open1007Pre Close449.71MTurnover151252wk High2.47%Turnover Ratio19.11MShares42952wk Low-71.3EPS TTM18.37BFloat Cap4530Historical HighLossP/E (Static)17.60MShs Float162Historical Low-67.9EPS LYR8.04%Amplitude--Dividend TTM6.60P/B100Lot Size--Div YieldTTM
About CanBas Company
CanBas Co Ltd focuses on the discovery and development of novel oncology drugs targeting the cell cycle. Its product, CBP501 the anticancer drug candidate is a modified synthetic peptide which enhances the efficacy of cisplatin without adding toxicity.
Company Profile
Symbol4575
Company NameCanBas
Founded2000-01-18
MarketTSE Growth
Fiscal Year Ends06-30
Address2-2-1 Otemachi Numazu
Zip Code410-0801
Phone055-954-3666
Websitewww.canbas.co.jp
Company Executives
- Name
- Position
- Salary
- Makoto Katozumi
- Chief Financial Officer and Head of Corporate Planning
- --
- Kazuyoshi Sakamoto
- Director and Manager of Administration
- --
- Takumi Kawabe
- Representative Director and President
- --
- Yasuyuki Komiyama
- Independent Director
- --
- Toshio Furuta
- Independent Director
- --
- Akira Shirakawa
- Independent Director
- --